Page 124 - Libro Memoria Cien Inglés

To achieve impact there is a need to of genetic and epigenetic protective
encourage novel as well as multidisci-
plinary approaches, and to strengthen
and extend existing capabilities across
the full spectrum of basic, clinical, heal-
th and social care, and translational re-
search. To that end, a number of priori-
ty areas for future research have been
identified: The origins of neurodegene-
rative diseases; Disease mechanisms
and models; Disease definition and
diagnosis; Treatment and prevention;
Health and social care.
This Research Strategy also provides a
framework of opportunities for coun-
tries involved in JPND and willing to
participate in joint actions, which will
be implemented through co-operative
activities that realign or link national
investments to achieve increased im-
pact, and the provision of new funding.
A guiding principle for its delivery will
be that the research to be supported is
of the highest scientific quality.
In this regard, during 2011 took place
the first call for European research
projects JPND. Under the theme "Op-
timization of biomarkers and harmo-
nization of their use in the clinic", four
transnational projects were awarded
for the period 2012-2015, with partici-
pation of the CIEN Foundation in in
one of them, the DEMTEST Project:
Biomarker based diagnosis of rapid
progressive dementias-optimization
of diagnostic protocols. Subsequent-
ly, at the end of 2012, a new call was
launched with the topic “Identification
Cien Foundation annual report 2020
and risk factors in neurodegenerative
diseases”, resolved with the approval of
five projects for the period 2014-2018.
During 2020 there have been no CIEN
Foundation research groups involved
in active projects within the joint Eu-
ropean Union program for research in
neurodegenerative diseases (JPND).
CENTERS OF EXCELLENCE IN
NEURODEGENERATION (CoEN)
A major obstacle to the advancement
of research on neurodegenerative
diseases is the relative lack of common
standards and mechanisms for vali-
dation of potentially relevant results in
preclinical studies, and clinical studies
based on population. One approach to
deal with these challenges on a large
scale is through a more effective use of
large centers and institutes, where the-
re is already the necessary critical mass
of resources and expertise. Increased
collaboration between national centers
of excellence should also provide the
opportunity to accelerate progress in
understanding the basic mechanisms
of disease, and the identification of
new therapeutic approaches.
To this end, on June 10, 2010, the Ca-
nadian Institutes of Health Research
(CIHR), the German Centre for Neu-
rodegenerative Diseases (DZNE,
Germany) and the Medical Research
Council (MRC, UK) launched a funding
initiative to establish a collaborative
124